Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Future Oncol
; 18(3): 403-412, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34787500
Lay abstracts The efficacy of PD-1 or PD-L1 inhibitors in patients with brain metastases of non-small-cell lung cancer (BM-NSCLC) is still inconclusive. We searched the electronic database of PubMed, Web of Science and Embase. All randomized controlled trials (RCTs) that compared the effectiveness of PD-1- or PD-L1-inhibitor-based treatment with non-PD-1/L1 inhibitor-based regimens in patients with NSCLC and reported the data of subgroup patients with brain metastases were eligible for inclusion. Finally, seven RCTs with 472 BM-NSCLC cases are included. All of these patients have been pretreated with local therapies and/or are asymptomatic for the brain lesions before joining the clinical trials. The pooled data of all trials indicated that PD-1- or PD-L1-inhibitor-based treatments reduced risk of disease progression of BM-NSCLC patients by 44% compared with non-PD-1/L1 inhibitor-based treatments. The results also showed that PD-1- or PD-L1-inhibitor-based treatments reduced risk of death of BM-NSCLC patients by 29% compared with non-PD-1/L1-inhibitor-based treatments. Our meta-analysis indicated that PD-1 or PD-L1 inhibitors can reduce risk of both disease progression and death in patients with brain metastases of NSCLC who have been pretreated with local therapies and/or are asymptomatic for the brain lesions.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Checkpoint Imunológico
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China